COVID-19 Impact on Boston Scientific Corp’s Revenue and Operations (Medical Devices)
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Boston Scientific is a medical technology company that designs, develops and markets equipment and instruments in the areas of cardiac surgery, general surgery, wound care management & neurological devices, headquartered in the US with global manufacturing and sales reach. Boston Scientific's product range includes equipment and instruments for cardiac surgery, gastro-enterology, interventional-cardiology, interventional-radiology, neurological surgery products, orthopaedic surgery products, pain medicine products, and urology products. The report, COVID-19 Impact on Boston Scientific Corp's Revenue and Operations (Medical Devices) presents a deep dive analysis into how Boston Scientific Corp is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.
Scope
The report provides a comprehensive analysis of the impact of COVID-19 on Boston Scientific Corp –
– It provides insights on Boston Scientific Corp's exposure to the regions and businesses impacted by the COVID-19 outbreak.
– It offers an overview of the company’s revenue impact by region and market for 2020 due to the COVID-19 outbreak.
Key Highlights
Boston Scientific’s Q3 2020 revenues reflected a reported loss of 1.8%. The company suffered losses in almost all of its segments this quarter, with MedSurge declining 2.3%, Rhythm and Neuro declining 3% and cardiovascular segment showing a decline of 5.9% on reported basis
Boston Scientific saw an increase in demand personal protective equipment (PPE) kits, and reusable personal respirators in Q3 due to the continuation of the pandemic. The company got approval for its new product, Pneumask face shield. The Pneumasks were donated to hospitals across the country
the expected results, the company did suffer an organic loss of 2.9% when sales dropped quickly in mid-March as hospitals and clinics canceled most procedures that could be delayed in order to conserve vital medical resources for fighting the pandemic and protecting healthcare workers from COVID-19.
Despite the impact on medical devices, its MedSurg had a 2.1% organic growth in Q1 2020. However, the Rhythm & Neuro segment suffered an organic loss of 8.6% and the Cardiovascular segment suffered a loss of 2.5%.
Boston Scientific might see an increase in demand for its resuscitator units (Coventor), personal protective equipment (PPE) kits, and reusable personal respirators in Q2 due to the continuation of the pandemic.
While all companies in the medical devices sector will see a major upheaval as a result of the disease, Boston Scientific is particularly exposed to downturns in its surgical workflows and medical devices sector which is showing signs of recovery.
Reasons to Buy
An overview of how Boston Scientific Corp will be affected by the COVID-19 pandemic.
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.